Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Generalized pustular psoriasis or von Zumbusch psoriasis. Red, painful, tender skin blotches show up over a wide area of your body, and pus-filled blisters pop up soon after.

German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe ...